Amicus Therapeutics (NASDAQ: FOLD)
Amicus Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Amicus Therapeutics Company Info
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.
News & Analysis
Why Amicus Therapeutics Stock Is Soaring Today
Investors cheered an analyst's upgrade of the biotech stock.
5 Absurdly Cheap Biotech Stocks That Could Make You Filthy Rich
These five biotech stocks could post life-changing gains for early-bird investors.
With the Market Down, I'm Buying These 3 Stocks
Amicus Therapeutics, Amarin, and CRISPR Therapeutics are all way oversold.
2 Top Biotech Stocks to Buy Right Now
These companies could crush the broader markets this year.
Why Amicus Therapeutics Stock Is Rising Today
An analyst upgrade is driving Amicus' stock higher today.
Is Amicus Therapeutics a Buy?
The gene therapy stock is trading at its lowest level in over two years. It recently announced preliminary third-quarter 2019 operating results.
Why Amicus Therapeutics Stock Folded in September
The competitive outlook for a key therapy is worrying investors.
Why Amicus Therapeutics Tanked in August
Investor concerns over the competitive outlook for the company's Pompe disease therapy candidate weighed on its stock price.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.